Journal
FRONTIERS IN PHARMACOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.951666
Keywords
retinal vein occlusion; macular edema; dexamethasone implant; anti-vascular endothelial growth factor; switching treatment; meta-analysis
Categories
Funding
- National Key Research and Development Project
- [2018YFC1106103]
Ask authors/readers for more resources
This meta-analysis demonstrates that switching therapy to DEX implants can significantly improve visual acuity and reduce central macular thickness in patients with refractory macular edema secondary to retinal vein occlusion. The efficacy can last for up to 6 months after a single-dose application.
Purpose: To assess the functional and anatomical consequences of single-dose dexamethasone (DEX) implants for the treatment of refractory macular edema (ME) secondary to retinal vein occlusion (RVO) after anti-vascular endothelial growth factor agents. Methods: A literature search of studies on switching therapy to DEX implants from anti-VEGF agents in refractory RVO patients was performed with five electronic databases (PubMed, Embase, Web of Science, MEDLINE, and Cochrane Library) prior to January 2022. The main outcomes included best-corrected visual acuity (BCVA) and central macular thickness (CMT) changes at different follow-up endpoints from baseline. All analyses were performed using Stata version 15.0. Results: The final analysis included four eligible studies with a total of 99 patients. After single-dose DEX implant application, BCVA improved significantly at 2, 3, and 6 months with an average gain of -0.23 logarithm of the minimum angle of resolution (logMAR) (p = 0.004), -0.20 logMAR (p = 0.027), and -0.09 logMAR (p = 0.021), respectively. Mean CMT reduction was also significant from baseline to 2 months (-241.89 mu m, p < 0.001), 3 months (-222.61 mu m, p < 0.001), and 6 months (-90.49 mu m, p < 0.001). No serious adverse events were observed in any of the included studies. Conclusion: This meta-analysis showed that RVO patients with refractory ME could benefit significantly from switching therapy to DEX implantation, with efficacy lasting 6 months after a single-dose application. Intravitreal DEX implantation is a safe and effective option for refractory cases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available